A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF ALXN1850 VERSUS PLACEBO ADMINISTERED SUBCUTANEOUSLY IN PEDIATRIC (2 TO < 12 YEARS OF AGE) PARTICIPANTS WITH HYPOPHOSPHATASIA WHO HAVE NOT RECEIVED PREVIOUS TREATMENT WITH ASFOTASE ALFA

Registry ID

ALXN1850-HPP-305

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ALEXION PHARMACEUTICALS INC

Start date

2024-05-23

Last update

2023-11-23

Conditions

• HYPOPHOSPHATASIA

Related clinical trials

• A PHASE 3, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM, ACTIVE-CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF ALXN1850 VERSUS ASFOTASE ALFA ADMINISTERED SUBCUTANEOUSLY IN PEDIATRIC PARTICIPANTS (2 TO < 12 YEARS OF AGE) WITH HYPOPHOSPHATASIA (HPP) PREVIOUSLY TREATED WITH ASFOTASE ALFA
• A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF ALXN1850 (RECOMBINANT ALKALINE PHOSPHATASE) ADMINISTERED SUBCUTANEOUSLY IN ADOLESCENT (12 TO < 18 YEARS OF AGE) AND ADULT PARTICIPANTS WITH HYPOPHOSPHATASIA WHO HAVE NOT PREVIOUSLY BEEN TREATED WITH ASFOTASE ALFA

View on source registry